VNT medicinos centras - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 320,404 | 413,687 | 462,904 | 608,938 | 717,971 | 1,041,206 | 1,536,522 | 1,739,314 |
| Profit before tax | - | - | - | - | - | 91,267 | 139,992 | 178,045 |
| Net profit | 21,376 | 86,198 | 75,355 | 92,384 | 123,033 | 77,577 | 118,993 | 149,558 |
| Equity | 25,881 | 91,079 | 79,434 | 167,684 | 307,965 | 399,864 | 539,856 | 695,528 |
| Liabilities | 26,032 | 19,186 | 37,307 | 212,411 | 349,234 | 948,047 | 878,693 | 583,007 |
| Non-current assets | 8,832 | 32,791 | 34,323 | 309,146 | 382,056 | 1,140,033 | 1,105,219 | 1,008,527 |
| Current assets | 41,576 | 76,545 | 81,523 | 69,883 | 269,475 | 203,189 | 306,217 | 265,741 |
| Total assets | 50,408 | 109,336 | 115,846 | 379,029 | 651,531 | 1,343,222 | 1,411,436 | 1,274,268 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 102,911 | 169,175 | 203,215 |
| Social insurance contributions | - | - | - | - | - | 122,067 | 192,016 | 240,417 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +54.0% | +29.1% | +11.9% | +31.5% | +17.9% | +45.0% | +47.6% | +13.2% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 42.4% | 78.8% | 65.0% | 24.4% | 18.9% | 5.8% | 8.4% | 11.7% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 82.6% | 94.6% | 94.9% | 55.1% | 40.0% | 19.4% | 22.0% | 21.5% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 6.7% | 20.8% | 16.3% | 15.2% | 17.1% | 7.5% | 7.7% | 8.6% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | - | 8.8% | 9.1% | 10.2% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 1.0 | 0.2 | 0.5 | 1.3 | 1.1 | 2.4 | 1.6 | 0.8 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 26,155 | 35,459 | 26,326 | 25,461 | 27,526 | 35,698 | 39,230 | 39,159 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
VNT medicinos centras - Social security debts
The company had no debts to Sodra
VNT medicinos centras - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-06-05 | 2026-06-05 | 8690.49 |
| 2026-06-04 | 2026-06-04 | 21644.05 |
| 2026-04-24 | 2026-04-28 | 100.39 |
| 2026-01-23 | 2026-01-23 | 935.24 |
| 2025-04-14 | 2025-04-14 | 14555.63 |
| 2025-04-12 | 2025-04-13 | 14500.75 |
| 2025-03-16 | 2025-03-17 | 13864.12 |
| 2025-03-15 | 2025-03-15 | 13812.04 |
| 2025-02-15 | 2025-02-15 | 12736.87 |
| 2025-02-14 | 2025-02-14 | 12682.56 |
| 2024-12-14 | 2024-12-14 | 13023.39 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
VNT medicinos centras, UAB (code 302821422), is a Private Limited Liability Company engaged in medical specialists activities. In the latest financial year, 2025, the company generated €1.74M in revenue and €149.6K in net profit, corresponding to an 8.6% profit margin. Performance improved steadily over the last three years: revenue rose from €1.04M in 2023 to €1.54M in 2024 and €1.74M in 2025, while net profit increased from €77.6K to €119.0K and then to €149.6K. Equity strengthened from €399.9K in 2023 to €539.9K in 2024 and €695.5K in 2025, while liabilities declined from €948.0K to €878.7K and then to €583.0K. Total assets were €1.27M in 2025, with long-term assets of €1.01M and short-term assets of €265.7K. Key ratios point to solid profitability and balance sheet efficiency: ROE was 21.5%, ROA 11.7%, debt-to-equity 0.84, and asset turnover 1.36x. Revenue per employee was €39.5K and profit per employee €3.4K.